ArticleEuropean journal of histochemistry : EJH2022
Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas.
Article in European journal of histochemistry : EJH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 15 citations in OpenAlex.
- Integrative analysis of adiponectin-related genes reveals immune subtypes and prognostic significance in melanoma.Future science OA · 2026Article
- Advances in the molecular mechanisms and clinical applications of LEMD1 in tumor development and progression (Review).Molecular and clinical oncology · 2026Review
- STAT1 accelerates cutaneous melanoma progression through TUBB4A expression regulation.Molecular medicine reports · 2026Article
- The Molecular Mechanism and Therapeutic Progress in Glomus Tumor.Cancer medicine · 2026Review
- CXCL14 promotes osteosarcoma cell migration and invasion by inducing epithelial-to-mesenchymal transition.International journal of medical sciences · 2026Article
- Prognostic implications of a programmed cell death-related long non-coding RNA signature and its relevance to immune features in esophageal carcinoma.Translational cancer research · 2025Article
- Immunotherapeutic targeting of NY-ESO-1 in malignant meningiomas with TCR-transduced T-cells.Journal of neuro-oncology · 2025Article
- HOTTIP suppresses ferroptosis via mediating DGCR8/miR‑214‑3p/GPX4 regulatory axis in osteosarcoma.Oncology reports · 2025Article
- MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction.International journal of molecular medicine · 2025Article
- PD‑1/PD‑L1 immune checkpoint in bone and soft tissue tumors (Review).Molecular and clinical oncology · 2025Review
- Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy.Molecular medicine (Cambridge, Mass.) · 2025Review
- A useful mTORC1 signaling-related RiskScore model for the personalized treatment of osteosarcoma patients by using the bulk RNA-seq analysis.Discover oncology · 2024Article
- Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective.Vaccines · 2024Review
- Neoadjuvant chemotherapy plus immunotherapy for locally advanced esophageal cancer.American journal of translational research · 2024Article
- Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.Molecules and cells · 2023Review
- Tumor cells-derived exosomal PD-L1 promotes the growth and invasion of lung cancer cells <em>in vitro via</em> mediating macrophages M2 polarization.European journal of histochemistry : EJH · 2023Article
- Antitumor effects of NK cells expanded by activation pre‑processing of autologous feeder cells before irradiation in colorectal cancer.Oncology letters · 2023Article
- Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review).International journal of oncology · 2023Review
- Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma.OncoTargets and therapy · 2022Article
- Exploring oncology treatment strategies with tyrosine kinase inhibitors through advanced 3D models (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has altered the treatment paradigm for soft tissue sarcomas (STSs). Considering the limited information regarding the clinical significance of immunohistochemical markers in STS, the purpose of this study was to determine the clinical significance of programmed cell death-1 (PD-1), PD ligand-1 (PD-L1), New York esophageal squamous cell carcinoma-1 (NY-ESO-1), and melanoma-associated antigen-A4 (MAGE-A4) expression in STSs. Twenty-two patients (median age, 72.5 years) with STSs treated at our hospital were included in this study. The specimens obtained at the time of biopsy were used to perform immunostaining for PD-1, PD-L1, NY-ESO, and MAGE-A4. The rates of PD-1-, PD-L1-, NY-ESO-, and MAGE-A4-positive cells and cases were calculated. The correlations among the positive cell rates of the immunohistochemical markers as well as their correlations with the histological grade, tumor size, or maximum standardized uptake (SUVmax) value were also determined. The average rates of PD-1-, PD-L1-, NY-ESO-, and MAGE-A4-positive cells were 4.39%, 28.0%, 18.2%, and 39.4%, respectively. Although the PD-1-positive cell rate showed no correlation with the rates of NY-ESO-1- and MAGE-A4-positive cells, the PD-L1-positive cell rates showed strong positive correlations with the rates of NY-ESO-1- and MAGE-A4-positive cells. PD-1-, PD-L1-, NY-ESO-1-, and MAGE-A4-positive cell rates showed weak to moderate correlations with histological grade or tumor size, while the PD-1-, PD-L1-, and MAGE-A4-positive cell rates showed strong to very strong positive correlations with the SUVmax value. Thus, PD-1, PD-L1, NY-ESO, and MAGE-A4 expressions are correlated and may be involved in the aggressive elements of STSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.